In summary, we demonstrated that ET58, a highly specific chimeric anti-GPC3 antibody, can be successfully conjugated with standard MRI contrast agent for the safe and non-invasive detection of GPC3-positive HCC tumors. This evidence concerns the gene GPC3 and hepatocellular carcinoma.